Ser339

Site Information
EHHstLVstRHYRAP SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 5966574

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 3 , 4 , 5 , 6 )
Relevant cell line - cell type - tissue:	'3T3-L1, differentiated' (adipocyte) ( 3 ) , 'stem, embryonic' ( 6 ) , BaF3 ('B lymphocyte, precursor') [JAK3 (human), transfection] ( 1 ) , macrophage-peritoneum ( 4 ) , MEF (fibroblast) [p53 (mouse), homozygous knockout] ( 5 )

References
1	Degryse S, et al. (2017) Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia. Leukemia 32 28852199 Curated Info
2	Sacco F, et al. (2016) Glucose-regulated and drug-perturbed phosphoproteome reveals molecular mechanisms controlling insulin secretion. Nat Commun 7, 13250 27841257 Curated Info
3	Parker BL, et al. (2015) Targeted phosphoproteomics of insulin signaling using data-independent acquisition mass spectrometry. Sci Signal 8, rs6 26060331 Curated Info
4	Wu X, et al. (2012) Investigation of receptor interacting protein (RIP3)-dependent protein phosphorylation by quantitative phosphoproteomics. Mol Cell Proteomics 11, 1640-51 22942356 Curated Info
5	Hsu PP, et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-22 21659604 Curated Info
6	Li H, et al. (2009) SysPTM: a systematic resource for proteomic research on post-translational modifications. Mol Cell Proteomics 8, 1839-49 19366988 Curated Info